Ivermectin and Fenbendazole: What the Research Actually Shows

Two antiparasitic drugs have ended up at the center of an online conversation about cancer. One is approved for humans, one is not. Here's an honest look at what the science says, what it doesn't say, and why both drugs deserve more rigorous study than they've gotten.

Where this conversation came from

In 2016, a man named Joe Tippens was diagnosed with small-cell lung cancer that had spread throughout his body. His prognosis was poor. He was also enrolled in a clinical trial of an experimental immunotherapy called pembrolizumab (Keytruda). On the advice of a veterinarian, he began taking a canine dewormer — fenbendazole — alongside the trial drug. Months later, his scans showed no evidence of cancer.

Tippens attributed his remission to fenbendazole. His story spread on social media, and a large online community of people self-administering veterinary antiparasitics for cancer grew up around it. Around the same time, a parallel conversation emerged about ivermectin — another antiparasitic drug — based on a growing body of laboratory research suggesting possible anticancer activity.

The story is compelling. It's also scientifically complicated. Tippens was on an immunotherapy drug at the time of his remission that has, on its own, produced dramatic responses in a subset of patients with his type of cancer. Isolating the effect of one variable when two are changing at once is exactly what clinical trials are designed to do, and exactly what has not happened here.

Ivermectin: what it is and what it's approved for

Ivermectin was developed in the 1970s from a compound produced by the soil bacterium Streptomyces avermitilis. Its discovery was recognized with the 2015 Nobel Prize in Physiology or Medicine. It has been used safely in hundreds of millions of doses worldwide, primarily to treat parasitic diseases like river blindness (onchocerciasis) and intestinal threadworm (strongyloidiasis), both of which are FDA-approved indications in the United States. Topical ivermectin is also approved for rosacea and head lice.

At the doses used for these approved indications, ivermectin has a well-characterized safety profile. It is on the World Health Organization's list of essential medicines.

What the cancer research does and doesn't show

In the last decade, researchers have published a growing number of preclinical studies — meaning studies in cell cultures and animal models, not in humans — suggesting ivermectin may have effects on cancer-related pathways. Proposed mechanisms include inducing programmed cell death in certain tumor cell lines, interfering with the Wnt/β-catenin signaling pathway, disrupting mitochondrial function, and affecting cancer stem cell populations.

These findings are scientifically interesting. They are not the same thing as evidence that ivermectin treats cancer in people. Many compounds look promising in a dish and fail in humans, for reasons that include poor bioavailability, different pharmacokinetics, off-target effects at the doses required, and the sheer biological complexity of a tumor growing in a living person.

As of this writing, ivermectin is not approved by the FDA or any other major regulator as a cancer treatment. It is also not approved for the prevention or treatment of COVID-19, a separate controversy that the FDA, WHO, and multiple large randomized trials have addressed directly.

Fenbendazole: what it is and why it's different

Fenbendazole is a benzimidazole antiparasitic used widely in veterinary medicine — for dogs, cattle, sheep, goats, horses, and laboratory rodents. It has never been approved for human use by the FDA or the European Medicines Agency. It belongs to a broader chemical family that includes two drugs that are approved for humans: mebendazole and albendazole, both used to treat intestinal parasites.

Fenbendazole's mechanism is to bind to a protein called β-tubulin, which disrupts microtubule assembly inside parasite cells. Microtubules are also essential to cell division in human cells, which is why several well-established chemotherapy drugs — the taxanes (paclitaxel, docetaxel) and the vinca alkaloids (vincristine, vinblastine) — work by targeting microtubules, though through different binding sites and mechanisms. This mechanistic overlap is part of what drew researchers to the question of whether fenbendazole might have anticancer activity.

What the preclinical research shows

Laboratory studies have reported that fenbendazole can:

• Destabilize microtubules in human cancer cell lines
• Cause cell-cycle arrest in the G2/M phase
• Trigger apoptosis (programmed cell death) in some tumor cell types
• Inhibit glucose uptake and glycolysis in cancer cells
• Induce oxidative stress that preferentially affects cancer cells over normal cells in some models
• Slow tumor growth in mouse models of lymphoma, leukemia, hepatocellular carcinoma, and other cancers

These are real findings from real peer-reviewed studies. They are also early-stage findings, many at drug concentrations that may not be achievable in human blood, and some of which have not been consistently reproduced.

Cutting against them is a 2008 Stanford study, published in Cancer Research, that specifically set out to test whether fenbendazole affected tumor growth in rodent models. The authors concluded that their data did not support further testing of fenbendazole as a cancer therapy — though they left open the possibility that related benzimidazole compounds might be worth exploring. This is a reminder that the preclinical picture is mixed, not unanimous.

What the human evidence shows (and doesn't)

There have been no randomized controlled clinical trials of fenbendazole in humans for any cancer indication. What exists in the medical literature is a small number of case reports — published descriptions of individual patients who self-administered the drug, with varied outcomes. Some describe tumor regression. At least two describe drug-induced liver injury that resolved when the drug was discontinued. Reviews of anecdotal reports compiled from online communities describe hundreds of stories, but these lack the controls, follow-up, and verification that would let researchers draw conclusions.

It is worth acknowledging something the skeptical coverage sometimes glosses over: the reason no large human trials exist is not that researchers have tested fenbendazole in humans and found it ineffective. It's that the economic structure of drug development rewards patented, expensive molecules, and fenbendazole is an off-patent veterinary generic with no commercial sponsor. Multiple researchers and bioethicists have argued that this is a problem — that promising cheap drugs get stranded in scientific limbo because no one stands to profit from proving them out. A related compound, oxfendazole (a major metabolite of fenbendazole), has recently received FDA fast-track designation for developing it as a treatment for human trichuriasis, which is an interesting indicator that the regulatory path for benzimidazoles in humans is not closed.

But "more study is warranted" is not the same as "this drug treats cancer." Both statements can be true at once, and it's important to hold them separately.

Risks of self-administration

People who self-administer veterinary fenbendazole for cancer are taking on several risks that rarely make it into the online testimonials:

• Liver toxicity. Published case reports describe drug-induced hepatic dysfunction that required stopping the drug. In the reported cases, liver function recovered — but liver injury is not always reversible, and in a patient already dealing with cancer and possibly other treatments, it can meaningfully complicate care.
• Unknown interactions. Cancer patients are often on immunotherapy, targeted therapy, chemotherapy, or radiation. How fenbendazole interacts with these is essentially uncharacterized in humans. Some interactions could plausibly reduce the effectiveness of the primary treatment.
• Unstandardized dosing. Veterinary fenbendazole is formulated for animals, not people. There is no human-dose pharmacokinetic data to guide what "enough" or "too much" looks like in a person.
• Quality control. Veterinary products are not manufactured to human pharmaceutical standards. Purity, filler safety, and batch consistency may differ.
• Delayed or abandoned standard care. This is the risk oncologists worry about most. A patient who substitutes self-prescribed fenbendazole for an evidence-based treatment can lose a window in which the cancer was still treatable.

None of this is a moral judgment of patients who have tried it. For someone facing a grim prognosis, the calculus looks different than it does from the outside, and the impulse to try something — anything — is deeply human. The point is just that the risks are real and deserve to sit on the same page as the hopeful stories.

So where does that leave us?

Three things appear to be simultaneously true:

• There is enough preclinical signal from both ivermectin and fenbendazole that the question of their anticancer activity is a legitimate research question, not a crank idea.
• There is not enough human evidence — and in the case of fenbendazole, essentially none — to conclude that either drug is a safe or effective cancer treatment in people.
• The absence of human evidence is at least partly a consequence of how drug development is funded, and that's a structural problem worth taking seriously rather than dismissing.

The reasonable response to all three is the same: well-designed human clinical trials, run by independent researchers, with proper controls and endpoints. Several early-stage trials of benzimidazoles in oncology are in various stages of planning or recruitment. Until those generate results, the honest answer to "does fenbendazole cure cancer?" is "we don't know, and the people telling you they do know — in either direction — are going beyond what the evidence supports."

If you're a patient weighing this

A few things worth doing:

• Talk to your oncology team honestly. Many oncologists are more open to discussing repurposed drugs than patients fear, especially if you bring specific questions rather than a declaration. If yours isn't willing to engage at all, a second opinion is reasonable.
• Ask about actual clinical trials. ClinicalTrials.gov lists human studies of benzimidazoles and other repurposed agents. Enrolling in a trial is both safer and more useful to the broader evidence base than self-administration.
• If you're already taking something, tell your care team. Hiding a medication from your oncologist is the most dangerous version of this decision, because it prevents them from monitoring for interactions and liver effects.
• Be skeptical of sources — in both directions. Sites selling fenbendazole have an incentive to overstate the evidence. Sites dismissing it entirely sometimes gloss over legitimate preclinical work. The peer-reviewed literature is the least bad place to read from, even when it's harder going.